Compare BMHL & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BMHL | TNYA |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.9M | 168.2M |
| IPO Year | 2024 | 2021 |
| Metric | BMHL | TNYA |
|---|---|---|
| Price | $5.79 | $0.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.33 |
| AVG Volume (30 Days) | 919.0 | ★ 1.9M |
| Earning Date | 06-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.96 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $66.66 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.72 | $0.53 |
| 52 Week High | $6.35 | $2.35 |
| Indicator | BMHL | TNYA |
|---|---|---|
| Relative Strength Index (RSI) | 56.91 | 47.03 |
| Support Level | $5.58 | $0.66 |
| Resistance Level | $6.35 | $0.82 |
| Average True Range (ATR) | 0.23 | 0.03 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 87.00 | 56.85 |
Bluemount Holdings Ltd through its operating subsidiaries, is a Hong Kong-based consulting and advisory, financial services, and luxury timepiece trading provider. The Company provides consulting and advisory services on business development strategies, including seeking suitable transaction projects for business development or diversification and suitable business partners or investors for fund-raising projects. Its services are centered around three core offerings: Business Transformation, Strategy, and Transactions. The Company also sources, buys, and sells brand-new luxury branded timepieces. It operates through two reportable segments: security-related services and asset management, and trading of timepieces, with the trading of timepieces generating maximum revenue.
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.